BioNTech Investor Day Presentation Deck

Shingles Potential first-in-class mRNA-based shingles vaccine with blockbuster potential FIH Phase 1 trial 2H 2022 BioNTech and Pfizer global mRNA collaboration programs in infectious diseases FIH, first-in-human. COVID-19 COMIRNATY: globally leading franchise Variant-adapted vaccine launch planned for 2H 2022 BIONTECH + Pfizer Influenza Single-dose quadrivalent mRNA vaccine Phase 1 data update expected in 2022 NUM Building on a track record of rapid clinical development and successful global commercialization of infectious disease vaccines mRNA for ID FOR Pfizer Pfizer BIONTECH 63

View entire presentation